DOCSLIB.ORG

Healthcare Conference San Francisco, CA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Healthcare Conference San Francisco, CA 35th ANNUAL J.P. MORGAN January 9–12, 2017 Westin St. Francis Hotel Healthcare Conference San Francisco, CA SUNDAY, MONDAY, JANUARY 9 CONFERENCE AGENDA JANUARY 8 Grand Ballroom Colonial Room California West California East Elizabethan A/B Elizabethan C/D Alexandra’s (32nd Floor) Registration – Breakout: Borgia Room Breakout: Georgian Room Breakout: Olympic Room Breakout: Yorkshire Room Breakout: Sussex Room Private Companies Not-For-Profit Track Tower Salon A 6:30 AM Registration — Tower Salon, Lobby Level, Breakfast — Italian Foyer, Mezzanine Level 3:00 PM – 8:00 PM 7:20 AM Opening Remarks: Jeff Stute, Global Head of Healthcare Investment Banking, J.P. Morgan — Grand Ballroom, Mezzanine Level Stuck on You — MetaSub meta genomics research comes to the 7:30 AM Celgene Corporation Mallinckrodt Pharmaceuticals The Medicines Company Wright Medical Group N.V. Mettler-Toledo International, Inc. Autolus Kaiser Permanente Healthcare Conference Tower Salon Foyer 8:00 AM HCA Inc. Edwards Lifesciences Corp. Alexion Pharmaceuticals, Inc. Bruker Corporation Cellectis Intarcia Therapeutics, Inc. Intermountain Healthcare during Registration Children's Hospital Join a research study to 8:30 AM Novartis BioMarin Pharmaceutical Inc. Teladoc Fresenius Medical Care Waters Corporation AccentCare of Philadelphia look at the microbiome and DNA of your cell 9:00 AM Baxter International Inc. Jazz Pharmaceuticals plc Alnylam Pharmaceuticals, Inc. Molina Healthcare, Inc. Invacare NantBio Northwestern Medicine phone, as part of a global study on the genomics of our world’s cities. Teva Pharmaceutical Industries Vertex Pharmaceuticals 9:30 AM Royal Philips NV Catalent, Inc. ResMed Inc. 10X Genomics Dignity Health Ltd. Incorporated 5 minutes / Optional / Confidential 10:00 AM Medtronic plc Merck KGaA Darmstadt Germany Ionis Pharmaceuticals, Inc. Agios Aduro Biotech Sellas Life Sciences CHRISTUS Health Results to be presented Colonial on Wednesday, Room 10:30 AM Gilead Sciences Inc. Endo International plc Tenet Healthcare Corp. HMS Holdings Corp. Codiak Biosciences Henry Ford Health System January 11, 12:30 pm, California East Bayer AG Memorial Hermann Georgian 11:00 AM Nevro Radius Health, Inc. Genomic Health Inc. Ginkgo Bioworks Room (no breakout) Health System Georgian University of Maryland 11:30 AM Express Scripts Inc. Acorda Therapeutics, Inc. Surgical Care Affiliates Quality Systems AmeriHealth Caritas Room Medical System Ironwood Pharmaceuticals, 12:00 PM Luncheon — Grand Ballroom, Mezzanine Level Epizyme** Inc.** Meridian Bioscience, Inc.** OptiNose US Inc Keynote: Jamie Dimon, Chairman and Chief Executive Officer, JPMorgan Chase & Co. 12:30 PM Interviewed by: Carlos Hernandez, Head of Global Banking, J.P. Morgan — Grand Ballroom, Foyer Mezzanine Level 1:30 PM Incyte Corporation Patheon Select Medical NuVasive, Inc. NeoTract, Inc. Cleveland Clinic 2:00 PM Amgen Inc. Illumina, Inc Acceleron Pharma, Inc. Daiichi Sankyo Company, Limited Ascendis Pharma SoultionReach Northwell Health Acadia Healthcare 2:30 PM Johnson & Johnson Seattle Genetics, Inc. Neurocrine Biosciences, Inc. HealthEquity Moderna Therapeutics Mercy Health Company Inc Takeda Pharmaceutical Company 3:00 PM Allergan Plc Fresenius SE & Co KGaA Myriad Genetics Inc. Halozyme Therapeutics, Inc. ABILITY Network Advocate Health Care Limited 3:30 PM Regeneron Pharmaceuticals, Inc. Cardinal Health, Inc. Pacira Pharmaceuticals Envision Healthcare Corporation Insulet Corporation Varex Imaging Corporation Novant Health Blue Cross Blue Shield 4:00 PM Merck & Co., Inc. QIAGEN N.V. Santen Inc. Alder Biopharmaceuticals Inc. Insys Therapeutics, Inc. EXOS of Michigan 4:30 PM Biogen Akorn, Inc. Henry Schein Inc ARIAD Pharmaceuticals Inc. H. Lundbeck A/S Quanterix Corporation UW Health 5:00 PM Digital Health Panel — Colonial Room, Mezzanine Level NantHealth AveXis Edison Pharmaceuticals, Inc. 5:00 PM Fireside Chat with Andy Slavitt, CMS — California West, Second Floor 5:30 PM The Great Debate: Pricing, Innovation & Delivering Value in the New Era of Medicine — Grand Ballroom, Mezzanine Level **Breakout session will be held at 1:30 pm in corresponding room Agenda last updated 1/6/2017. Please check monitors located around the conference for agenda changes. #JPMHC35 35th ANNUAL J.P. MORGAN January 9–12, 2017 Westin St. Francis Hotel Healthcare Conference San Francisco, CA TUESDAY, JANUARY 10 CONFERENCE AGENDA Grand Ballroom Colonial Room California West California East Elizabethan A/B Elizabethan C Elizabethan D Alexandra’s (32nd Floor) Victor’s (32nd Floor) Breakout: Borgia Room Breakout: Georgian Room Breakout: Olympic Room Breakout: Yorkshire Room Breakout: Sussex Room Private Companies Private Companies Not-For-Profit Track Emerging Markets Track 7:00 AM Registration — Tower Salon, Lobby Level, Breakfast — Italian Foyer, Mezzanine Level Ultragenyx Pharmaceutical 7:30 AM Boston Scientific Corp. Horizon Pharma Plc Sarepta Quidel Corporation Landmark Health Sera Prognostics, Inc. Hackensack Meridian Inc. LTS Lohmann Therapie- 8:00 AM CVS Health CENTENE Corporation Perrigo Company plc Healthways, Inc. ICON plc GreatCall Ascension systeme Ag Zimmer Biomet Holdings, 8:30 AM Roche Holding AG Puma Biotechnology, Inc. Amicus Therapeutics, Inc. Emergent BioSolutions Inc. One Medical Group US Anesthesia Partners RWJBarnabas Health Inc. Integrated DNA 9:00 AM GlaxoSmithKline PLC Premier Inc. 3M Company Teleflex Incorporated Foundation Medicine G1 Therapeutics Presence Health Technologies Twist Bioscience 9:30 AM Bristol-Myers Squibb Co. C. R. Bard, Inc. Sage Therapeutics Five Prime Therapeutics Patterson Companies, Inc. Solid Biosciences IU Health Corporation Hospital Sisters Health 10:00 AM Sanofi McKesson Corporation DaVita Inc. Atara Biotherapeutics Zeltiq Aesthetics Amneal Pharmaceuticals Vascular Therapies System 10:30 AM Pfizer Inc. Hologic, Inc. Alkermes plc Dexcom, Inc. NanoString Technologies Inc Braeburn Pharmaceuticals Caris Life Sciences Marshfield Clinic True North Therapeutics, 11:00 AM Cerner Corp. Dentsply Sirona HealthSouth Corporation Hill-Rom Vets First Choice Geisinger Inc. The Advisory Board New York Presbyterian 11:30 AM Danaher Corp. Spark Therapeutics AMAG Pharmaceuticals, Inc. Oscar Insurance Dova Pharmaceuticals Company Healthcare System 12:00 PM Luncheon — Grand Ballroom, Mezzanine Level Samsung Biologics Co Ltd** Axovant Sciences** Ventas, Inc.** Sharecare, Inc. Intermédica Alexandra’s (32nd Floor) Victor’s (32nd Floor) 12:30 PM Keynote: Juan Enriquez, Co-Founder, Synthetic Genomics, Inc.; Former Director of the Harvard Business Life Sciences Project; Managing Director, Excel Venture Management Emerging Markets Track Emerging Markets Track Laboratory Corporation Charles River Laboratories Orchid Orthopedic Glenmark Pharmaceuticals 1:30 PM Penumbra, Inc. Acadia Pharmaceuticals Y-mAbs Therapeutics RaiaDrogasil of America Holdings Inc. Solutions, LLC Ltd 2:00 PM Varian Medical Systems Inc. Astellas Pharma Inc. Nektar Therapeutics Coherus BioSciences Inc NuCana DNAnexus Lupin Ltd Hypermarcas Thermo Fisher Allscripts Healthcare 2:30 PM Clovis Oncology Intersect ENT Bio-Techne Avantor Mersana Therapeutics Dr. Reddy’s Laboratories Ltd Genomma Lab Scientific Inc. Solutions, Inc. Momenta Pharmaceuticals Panasonic Healthcare 3:00 PM Shire plc Agilent Technologies Inc. Esperion Therapeutics, Inc. Global Blood Therapeutics Millendo Therapeutics Inc Cipla Ltd Grupo Biotoscana Inc. Holdings Co., Ltd. 3:30 PM AmerisourceBergen Corp. Pacific Biosciences The Cooper Companies Ardelyx Ignyta Tricida, Inc. Universal Hospital Services Aurobindo Pharma Ltd OdontoPrev 4:00 PM Abbott Labs PAREXEL International Corp. Otsuka Holdings Co., Ltd. Inogen Inc Supernus Principia Biopharma Ortho Clinical Diagnostics Torrent Pharmaceuticals Ltd Fleury Universal Health Services, Healthcare Global 4:30 PM Eli Lilly and Co. Juno Therapeutics, Inc. Bio-Rad Laboratories, Inc. Lonza Group AG CareCentrix Envisia Therapeutics Inc. Ourofino Inc. Enterprises Ltd Valeant Pharmaceuticals Diagnostics Outlook Pnl Karyopharm Therapeutics 5:00 PM Audentes Therapeutics, Inc. AngioDynamics, Inc. AncestryDNA Xenex International Colonial Room Inc **Breakout session will be held at 1:30 pm in corresponding room Agenda last updated 1/6/2017. Please check monitors located around the conference for agenda changes. #JPMHC35 35th ANNUAL J.P. MORGAN January 9–12, 2017 Westin St. Francis Hotel Healthcare Conference San Francisco, CA WEDNESDAY, JANUARY 11 CONFERENCE AGENDA Grand Ballroom Colonial Room California West California East Elizabethan A Elizabethan B Elizabethan D Alexandra’s (32nd Floor) Victor’s (32nd Floor) Breakout: Borgia Room Breakout: Georgian Room Breakout: Olympic Room Breakout: Yorkshire Room Breakout: Sussex Room Breakout: Elizabethan C Private Companies Emerging Markets Track Emerging Markets Track 7:00 AM Registration — Tower Salon, Lobby Level, Breakfast — Italian Foyer, Mezzanine Level 7:30 AM Stryker Corp. athenahealth, Inc. ZIOPHARM Oncology PTC Therapeutics, Inc. Insmed Incorporated TherapeuticsMD Aprea Therapeutics 8:00 AM AbbVie MEDNAX, Inc. PerkinElmer, Inc. Endologix BTG Plc Molecular Partners AG Axcella Berry Genomics Co Ltd Green Cross Corp Becton, Dickinson Lee’s Pharmaceutical Celltrion Inc / 8:30 AM Diplomat Pharmacy, Inc. Chimerix, Inc. Array BioPharma Inc. Essilor International VWR Corporation Kiniksa Pharmaceuticals and Company Holdings Ltd Celltrion Healthcare 9:00 AM Mylan N.V. Intrexon Corporation OPKO Health, Inc. ConMed Corporation Enanta Pharmaceuticals Inc. Ipsen SA Young Innovations Inc Ascentage
Load more

Recommended publications
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • March 31, 2021
    Units Cost Market Value US Equity Index Fund US Equities 95.82% Domestic Common Stocks 10X GENOMICS INC 126 10,868 24,673 1LIFE HEALTHCARE INC 145 6,151 4,794 2U INC 101 5,298 4,209 3D SYSTEMS CORP 230 5,461 9,193 3M CO 1,076 182,991 213,726 8X8 INC 156 2,204 4,331 A O SMITH CORP 401 17,703 28,896 A10 NETWORKS INC 58 350 653 AAON INC 82 3,107 5,132 AARON'S CO INC/THE 43 636 1,376 ABBOTT LABORATORIES 3,285 156,764 380,830 ABBVIE INC 3,463 250,453 390,072 ABERCROMBIE & FITCH CO 88 2,520 4,086 ABIOMED INC 81 6,829 25,281 ABM INDUSTRIES INC 90 2,579 3,992 ACACIA RESEARCH CORP 105 1,779 710 ACADIA HEALTHCARE CO INC 158 8,583 9,915 ACADIA PHARMACEUTICALS INC 194 6,132 4,732 ACADIA REALTY TRUST 47 1,418 1,032 ACCELERATE DIAGNOSTICS INC 80 1,788 645 ACCELERON PHARMA INC 70 2,571 8,784 ACCO BRANDS CORP 187 1,685 1,614 ACCURAY INC 64 483 289 ACI WORLDWIDE INC 166 3,338 6,165 ACTIVISION BLIZZARD INC 1,394 52,457 133,043 ACUITY BRANDS INC 77 13,124 14,401 ACUSHNET HOLDINGS CORP 130 2,487 6,422 ADAPTHEALTH CORP 394 14,628 10,800 ADAPTIVE BIOTECHNOLOGIES CORP 245 11,342 10,011 ADOBE INC 891 82,407 521,805 ADT INC 117 716 1,262 ADTALEM GLOBAL EDUCATION INC 99 4,475 3,528 ADTRAN INC 102 2,202 2,106 ADVANCE AUTO PARTS INC 36 6,442 7,385 ADVANCED DRAINAGE SYSTEMS INC 116 3,153 13,522 ADVANCED ENERGY INDUSTRIES INC 64 1,704 7,213 ADVANCED MICRO DEVICES INC 2,228 43,435 209,276 ADVERUM BIOTECHNOLOGIES INC 439 8,321 1,537 AECOM 283 12,113 17,920 AERIE PHARMACEUTICALS INC 78 2,709 1,249 AERSALE CORP 2,551 30,599 31,785 AES CORP/THE 1,294 17,534 33,735 AFFILIATED
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • ENDO INTERNATIONAL PLC (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): January 16, 2015 ENDO INTERNATIONAL PLC (Exact name of registrant as specified in its charter) Ireland 001-36326 Not Applicable (State or other jurisdiction of (Commission (I.R.S Employer incorporation or organization) File Number) Identification No.) Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland Not Applicable (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code 011-353-1-268-2000 Not Applicable Former name or former address, if changed since last report Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01 Other Events. This Current Report on Form 8-K is being filed pursuant to a memorandum of understanding regarding the settlement of certain litigation relating to the proposed merger (the “Merger”) between Auxilium Pharmaceuticals, Inc. (“Auxilium”) and Avalon Merger Sub Inc. (“Merger Sub”) pursuant to that certain Amended and Restated Agreement and Plan of Merger, dated as of November 17, 2014 (the “Merger Agreement”), by and among Auxilium, Endo International plc (“Endo”), Endo U.S.
    [Show full text]
  • US Pharma's Business Model
    INNOVATION-FUELLED, SUSTAINABLE, INCLUSIVE GROWTH Working Paper US Pharma’s Business Model: Why It Is Broken, and How It Can Be Fixed William Lazonick Matt Hopkins Ken Jacobson Mustafa Erdem Sakinç Öner Tulum The Academic-Industry Research Network 13/2017 May This project has received funding from the European Union Horizon 2020 Research and Innovation action under grant agreement No 649186 US Pharma’s Business Model: Why It Is Broken, and How It Can Be Fixed William Lazonick Matt Hopkins Ken Jacobson Mustafa Erdem Sakinç Öner Tulum The Academic-Industry Research Network (www.theAIRnet.org) Revised, May 22, 2017 Chapter for inclusion in David Tyfield, Rebecca Lave, Samuel Randalls, and Charles Thorpe, eds., The Routledge Handbook of the Political Economy of Science The contents of this chapter are drawn from two contributions by the Academic- Industry Research Network to the United Nations Secretary-General’s High-Level Panel on Access to Medicines: http://www.unsgaccessmeds.org/list-of-contribution/ William Lazonick is Professor of Economics, University of Massachusetts Lowell; Visiting Professor, University of Ljubljana; Professeur Associé, Institut Mines- Télécom; and President, The Academic-Industry Research Network (theAIRnet); Matt Hopkins, Ken Jacobson, Mustafa Erdem Sakinç, and Öner Tulum are researchers at theAIRnet. Jacobson is also theAIRnet communications director. Sakinç has just completed a PhD in economics at the University of Bordeaux. Tulum is a PhD student at the University of Ljubljana. Funding for this research came from the Institute for New Economic Thinking (Collective and Cumulative Careers project), the European Union Horizon 2020 Research and Innovation Programme under grant agreement No.
    [Show full text]
  • The Top 15 Generic Drugmakers of 2016 by Eric Sagonowsky, Eric Palmer, Angus Liu
    The top 15 generic drugmakers of 2016 by Eric Sagonowsky, Eric Palmer, Angus Liu Branded drugmakers weren’t the only ones working through a tumultuous 2016. Generics companies faced pricing pressure, too. And while branded companies suffer pricing pain on costly cutting-edge therapies, generics outfits feel the pinch with already-thin margins, making pressure all the more agonizing. How is the industry responding? By consolidating and hoping to save money, for one. Take a look at FiercePharma’s 2014 ranking, and it’s clear that some companies have made leaps too big to depend on organic growth alone. Take Teva, which topped the 2016 list as it did in 2014. It wrapped up the biggest M&A move in recent history for the generics industry, swallowing Allergan’s unbranded offerings for $40.5 billion in August. The massive move will continue to reverberate in the generics industry for years to come. Top drugmakers by 2016 generics revenue in USD billions Teva Pharmaceutical Industries 9.85 Mylan 9.43 Novartis 9 Pfizer 4.57 Allergan 4.5 Sun Pharmaceutical Industries 3.61 Fresenius 2.8 Endo International 2.57 Lupin 2.49 Sanofi 2.05 Aspen Pharmacare 2 Aurobindo Pharma 1.86 Dr. Reddy's Laboratories 1.78 Cipla 1.61 Apotex 1.6 Source: Evaluate, May 2017 Get the data Sales data for Sun Pharma, Fresenius, Lupin, Aspen Pharmacare, Aurobindo, Cipla, and Apotex are Evaluate estimates. Dr. Reddy’s data provided from company filing. Behind Teva came Mylan, which also completed a big deal last year, a $7.2 billion buyout of Sweden’s Meda.
    [Show full text]
  • L'institution Royale Pour L'avancement
    L’INSTITUTION ROYALE POUR L’AVANCEMENT DES SCIENCES / UNIVERSITÉ McGILL ACTIONS AMÉRICAINES │ au 31 mars 2019 Actions américaines d’une valeur supérieure à 500 000 $ cotées en bourse et détenues dans des comptes distincts (en $ CAN) GRAND CANYON EDUCATION INC 2 464 502 WADDELL & REED FINANCIAL INC 838 294 VIRTU FINANCIAL INC 2 098 163 DXP ENTERPRISES INC/TX 829 531 EURONET WORLDWIDE INC 2 075 232 OSHKOSH CORP 772 848 IRIDIUM COMMUNICATIONS INC 2 021 967 CIENA CORP 748 266 MARKETAXESS HOLDINGS INC 1 969 545 SNAP‐ON INC 710 950 UNIVERSAL HEALTH SERVICES INC 1 924 707 PULTEGROUP INC 705 975 MAXIMUS INC 1 697 760 VISHAY INTERTECHNOLOGY INC 703 237 ENVESTNET INC 1 539 593 UNUM GROUP 659 850 CHARLES RIVER LABORATORIES INT 1 531 805 LEAR CORP 652 686 CHEMED CORP 1 484 619 JETBLUE AIRWAYS CORP 649 127 MARRIOTT VACATIONS WORLDWIDE C 1 442 976 AVNET INC 643 136 US SILICA HOLDINGS INC 1 434 222 AMC NETWORKS INC 636 960 ACUSHNET HOLDINGS CORP 1 352 421 HUNTINGTON INGALLS INDUSTRIES 636 660 GENTHERM INC 1 321 685 WESTROCK CO 635 298 LAUREATE EDUCATION INC 1 308 706 CIT GROUP INC 628 038 FOX FACTORY HOLDING CORP 1 274 121 DOMTAR CORP 623 501 HURON CONSULTING GROUP INC 1 242 872 REGIONS FINANCIAL CORP 614 370 INTL. FCSTONE INC 1 242 806 ARBOR REALTY TRUST INC 608 950 RE/MAX HOLDINGS INC 1 238 584 QUEST DIAGNOSTICS INC 600 643 TEMPUR SEALY INTERNATIONAL INC 1 225 928 OWENS CORNING 598 025 GLOBUS MEDICAL INC 1 212 789 GLOBAL BRASS & COPPER HOLDINGS 593 531 THERMON GROUP HOLDINGS INC 1 209 830 FEDERAL AGRICULTURAL MORTGAGE 590 253 SHUTTERSTOCK INC 1 202
    [Show full text]
  • BNYM Investment Port:Midcap Stock Port (Unaudited) As of Date: 09/30/2020 Common Stocks
    BNYM Investment Port:MidCap Stock Port (Unaudited) As of date: 09/30/2020 Common Stocks Identifier Security Description Shares Market Value ($) 002535300 Aaron's 7,450 422,043 00404A109 Acadia Healthcare 5,480 161,550 004498101 ACI Worldwide 13,250 346,223 00508Y102 Acuity Brands 9,470 969,255 BD845X2 Adient 12,480 216,278 00737L103 Adtalem Global Education 6,800 166,872 00766T100 AECOM 4,170 174,473 018581108 Alliance Data Systems 7,130 299,317 01973R101 Allison Transmission Holdings 7,110 249,845 00164V103 AMC Networks 10,710 264,644 023436108 Amedisys 2,760 652,547 025932104 American Financial Group 3,310 221,704 03073E105 AmerisourceBergen 2,220 215,162 042735100 Arrow Electronics 5,620 442,069 04280A100 Arrowhead Pharmaceuticals 5,670 244,150 045487105 Associated Banc-Corp 47,940 605,003 05329W102 Autonation 6,980 369,451 05368V106 Avient 23,030 609,374 053774105 Avis Budget Group 10,600 278,992 05464C101 Axon Enterprise 2,410 218,587 062540109 Bank of Hawaii 4,830 244,012 06417N103 Bank OZK 6,630 141,352 090572207 Bio-Rad Laboratories 1,480 762,881 09073M104 Bio-Techne 880 218,002 05550J101 BJs Wholesale Club Holdings 11,270 468,269 09227Q100 Blackbaud 3,750 209,363 103304101 Boyd Gaming 18,350 563,162 105368203 Brandywine Realty Trust 93,500 966,790 11120U105 Brixmor Property Group 6,300 73,647 117043109 Brunswick 8,150 480,117 12685J105 Cable One 300 565,629 127190304 CACI International, Cl. A 3,980 848,377 12769G100 Caesars Entertainment 11,890 666,553 133131102 Camden Property Trust 11,390 1,013,482 134429109 Campbell Soup 4,440
    [Show full text]
  • P39262 Alimera Sciences, Inc. Nps 2020 V1
    Alimera Sciences, Inc. 6120 Windward Parkway, Suite 290 Alpharetta, Georgia 30005 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 18, 2020 To the Stockholders of Alimera Sciences, Inc.: The annual meeting of stockholders (the “Annual Meeting”) of Alimera Sciences, Inc. (the “Company”) will be held exclusively online via the Internet on Thursday, June 18, 2020, at 9:30 a.m. Eastern Time. The purposes of the meeting are: 1. To elect three Class I directors (Proposal 1); 2. To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020 (Proposal 2); 3. To approve, on an advisory basis, the compensation of our named executive officers (Proposal 3); and 4. To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof. Our board of directors (the “Board”) has fixed the close of business on April 20, 2020 as the record date (the “record date”) for determining holders of our common stock and preferred stock entitled to notice of, and to vote at, the Annual Meeting or any adjournments or postponements thereof. This year we are again using the Internet as our primary means of furnishing proxy materials to stockholders. Accordingly, most stockholders will not receive printed copies of our proxy materials. We are instead mailing a Notice of Internet Availability of Proxy Materials with instructions for accessing the proxy materials and voting via the Internet (the “Notice”). This delivery method allows us to conserve natural resources and reduce the cost of delivery while also meeting our obligations to you, our stockholders, to provide information relevant to your continued investment in the Company.
    [Show full text]
  • Usef-I Q2 2021
    Units Cost Market Value U.S. EQUITY FUND-I U.S. Equities 88.35% Domestic Common Stocks 10X GENOMICS INC 5,585 868,056 1,093,655 1ST SOURCE CORP 249 9,322 11,569 2U INC 301 10,632 12,543 3D SYSTEMS CORP 128 1,079 5,116 3M CO 11,516 2,040,779 2,287,423 A O SMITH CORP 6,897 407,294 496,998 AARON'S CO INC/THE 472 8,022 15,099 ABBOTT LABORATORIES 24,799 2,007,619 2,874,948 ABBVIE INC 17,604 1,588,697 1,982,915 ABERCROMBIE & FITCH CO 1,021 19,690 47,405 ABIOMED INC 9,158 2,800,138 2,858,303 ABM INDUSTRIES INC 1,126 40,076 49,938 ACACIA RESEARCH CORP 1,223 7,498 8,267 ACADEMY SPORTS & OUTDOORS INC 1,036 35,982 42,725 ACADIA HEALTHCARE CO INC 2,181 67,154 136,858 ACADIA REALTY TRUST 1,390 24,572 30,524 ACCO BRANDS CORP 1,709 11,329 14,749 ACI WORLDWIDE INC 6,138 169,838 227,965 ACTIVISION BLIZZARD INC 13,175 839,968 1,257,422 ACUITY BRANDS INC 1,404 132,535 262,590 ACUSHNET HOLDINGS CORP 466 15,677 23,020 ADAPTHEALTH CORP 1,320 39,475 36,181 ADAPTIVE BIOTECHNOLOGIES CORP 18,687 644,897 763,551 ADDUS HOMECARE CORP 148 13,034 12,912 ADOBE INC 5,047 1,447,216 2,955,725 ADT INC 3,049 22,268 32,899 ADTALEM GLOBAL EDUCATION INC 846 31,161 30,151 ADTRAN INC 892 10,257 18,420 ADVANCE AUTO PARTS INC 216 34,544 44,310 ADVANCED DRAINAGE SYSTEMS INC 12,295 298,154 1,433,228 ADVANCED MICRO DEVICES INC 14,280 895,664 1,341,320 ADVANSIX INC 674 15,459 20,126 ADVANTAGE SOLUTIONS INC 1,279 14,497 13,800 ADVERUM BIOTECHNOLOGIES INC 1,840 7,030 6,440 AECOM 5,145 227,453 325,781 AEGLEA BIOTHERAPEUTICS INC 287 1,770 1,998 AEMETIS INC 498 6,023 5,563 AERSALE CORP
    [Show full text]
  • Wilmington Funds Holdings Template DRAFT
    Wilmington Large-Cap Strategy Fund as of 5/31/2021 (Portfolio composition is subject to change) ISSUER NAME % OF ASSETS APPLE INC 4.97% MICROSOFT CORP 4.69% AMAZON.COM INC 3.45% FACEBOOK INC 1.99% ALPHABET INC 1.80% ALPHABET INC 1.77% BERKSHIRE HATHAWAY INC 1.48% JPMORGAN CHASE & CO 1.35% TESLA INC 1.20% JOHNSON & JOHNSON 1.12% UNITEDHEALTH GROUP INC 0.98% VISA INC 0.96% NVIDIA CORP 0.96% BANK OF AMERICA CORP 0.89% HOME DEPOT INC/THE 0.87% WALT DISNEY CO/THE 0.82% MASTERCARD INC 0.80% PAYPAL HOLDINGS INC 0.77% EXXON MOBIL CORP 0.68% PROCTER & GAMBLE CO/THE 0.67% COMCAST CORP 0.66% ADOBE INC 0.62% INTEL CORP 0.59% VERIZON COMMUNICATIONS INC 0.59% CISCO SYSTEMS INC 0.57% CHEVRON CORP 0.55% PFIZER INC 0.54% NETFLIX INC 0.54% AT&T INC 0.53% SALESFORCE.COM INC 0.53% ABBOTT LABORATORIES 0.51% ABBVIE INC 0.50% MERCK & CO INC 0.48% WELLS FARGO & CO 0.48% BROADCOM INC 0.47% THERMO FISHER SCIENTIFIC INC 0.47% ACCENTURE PLC 0.46% CITIGROUP INC 0.45% MCDONALD'S CORP 0.44% TEXAS INSTRUMENTS INC 0.44% COCA-COLA CO/THE 0.44% HONEYWELL INTERNATIONAL INC 0.44% LINDE PLC 0.43% MEDTRONIC PLC 0.43% NIKE INC 0.43% ELI LILLY & CO 0.42% PEPSICO INC 0.42% UNITED PARCEL SERVICE INC 0.41% WALMART INC 0.40% DANAHER CORP 0.40% UNION PACIFIC CORP 0.40% QUALCOMM INC 0.38% BRISTOL-MYERS SQUIBB CO 0.37% ORACLE CORP 0.37% LOWE'S COS INC 0.36% BLACKROCK INC 0.35% CATERPILLAR INC 0.35% AMGEN INC 0.35% BOEING CO/THE 0.35% MORGAN STANLEY 0.35% COSTCO WHOLESALE CORP 0.35% RAYTHEON TECHNOLOGIES CORP 0.34% STARBUCKS CORP 0.34% GOLDMAN SACHS GROUP INC/THE 0.34% GENERAL ELECTRIC
    [Show full text]
  • UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT of FLORIDA Miami Division in Re: MIAMI INTERNATIONAL MEDI
    Case 18-12741-LMI Doc 97 Filed 04/03/18 Page 1 of 23 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF FLORIDA Miami Division www.flsb.uscourts.gov In re: MIAMI INTERNATIONAL MEDICAL CENTER, LLC1 Case No. 18-12741-LMI d/b/a THE MIAMI MEDICAL CENTER, Chapter 11 Debtor. / SUPPLEMENTAL CERTIFICATE OF SERVICE I HEREBY CERTIFY that a true and correct copy of the Debtor’s Motion for Entry of (A) an Order Approving Bidding Procedures, (B) Approving Certain Protections to Stalking Horse Purchaser, (C) Approving Notice Procedures, and (D) an Order (I) Approving the Asset Purchase Agreement, (II) Authorizing the Sale of all or Substantially all of the Assets of the Debtor Free and Clear of all Liens, Claims, Encumbrances and Other Interests, (III) Authorizing the Assumption and Assignment of Certain Executory Contracts and Unexpired Leases, (IV) Scheduling Dates to Conduct Auction and Hearing to Consider Final Approval of Sale, and (V) Granting Related Relief [ECF No. 84] was served via Regular U.S. Mail on April 2, 2018, on all REMAINDER OF PAGE LEFT INTENTIONALLY BLANK 1The Debtor’s current mailing address is 5959 NW 7 St, Miami, FL 33126 and its EIN ends 4362. 1 LAW OFFICES OF MELAND RUSSIN & BUDWICK, P.A. 3200 SOUTHEAST FINANCIAL CENTER, 200 SOUTH BISCAYNE BOULEVARD, MIAMI, FLORIDA 33131 • TELEPHONE (305) 358-6363 Case 18-12741-LMI Doc 97 Filed 04/03/18 Page 2 of 23 parties listed on the Court’s Matrix attached hereto as Exhibit 12, and to all parties listed on the Patients Matrix which was filed under seal pursuant to Court Order [ECF No.
    [Show full text]